Financhill
Sell
42

REGN Quote, Financials, Valuation and Earnings

Last price:
$715.04
Seasonality move :
10.8%
Day range:
$700.83 - $717.61
52-week range:
$693.00 - $1,211.20
Dividend yield:
0%
P/E ratio:
17.37x
P/S ratio:
5.83x
P/B ratio:
2.63x
Volume:
1.9M
Avg. volume:
900.7K
1-year change:
-16.62%
Market cap:
$77.1B
Revenue:
$13.1B
EPS (TTM):
$40.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
REGN
Regeneron Pharmaceuticals
$3.7B $11.70 9.55% 7.9% $1,053.08
ABBV
AbbVie
$14.3B $2.92 3.54% 547.15% $202.54
AMGN
Amgen
$8.5B $5.11 8.07% 255.18% $322.43
BIIB
Biogen
$2.4B $3.79 1.22% 101.89% $242.83
LLY
Eli Lilly and
$12.1B $1.47 49.68% 124.93% $984.05
PFE
Pfizer
$14.9B $0.61 27.51% 12.4% $31.86
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
REGN
Regeneron Pharmaceuticals
$701.85 $1,053.08 $77.1B 17.37x $0.00 0% 5.83x
ABBV
AbbVie
$175.58 $202.54 $310.3B 60.97x $1.55 3.53% 5.61x
AMGN
Amgen
$263.38 $322.43 $141.6B 33.72x $2.25 3.42% 4.37x
BIIB
Biogen
$146.47 $242.83 $21.3B 13.23x $0.00 0% 2.23x
LLY
Eli Lilly and
$767.76 $984.05 $728.8B 83.00x $1.30 0.68% 16.99x
PFE
Pfizer
$26.36 $31.86 $149.4B 35.62x $0.42 6.37% 2.52x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
REGN
Regeneron Pharmaceuticals
6.34% 1.460 1.71% 4.34x
ABBV
AbbVie
92.18% 0.492 20.37% 0.44x
AMGN
Amgen
88.92% -0.086 34.87% 0.80x
BIIB
Biogen
27.78% 0.334 22.29% 0.68x
LLY
Eli Lilly and
68.61% 0.948 3.9% 0.63x
PFE
Pfizer
41.92% 0.516 40.56% 0.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
REGN
Regeneron Pharmaceuticals
$3.2B $1.2B 16.02% 17.19% 40.5% $1B
ABBV
AbbVie
$10.2B $3.9B 6.75% 58.92% 19.39% $5.2B
AMGN
Amgen
$5.2B $2B 6.14% 65.35% 45.6% $3.3B
BIIB
Biogen
$1.8B $496.4M 7.34% 10.52% 20.72% $805.6M
LLY
Eli Lilly and
$9.3B $4.4B 21.5% 66.4% 15.57% -$458.9M
PFE
Pfizer
$12.4B $5.3B 2.66% 4.63% 31.06% $6.1B

Regeneron Pharmaceuticals vs. Competitors

  • Which has Higher Returns REGN or ABBV?

    AbbVie has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 10.8%. Regeneron Pharmaceuticals's return on equity of 17.19% beat AbbVie's return on equity of 58.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
    ABBV
    AbbVie
    70.87% $0.88 $77.2B
  • What do Analysts Say About REGN or ABBV?

    Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand AbbVie has an analysts' consensus of $202.54 which suggests that it could grow by 15.36%. Given that Regeneron Pharmaceuticals has higher upside potential than AbbVie, analysts believe Regeneron Pharmaceuticals is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    REGN
    Regeneron Pharmaceuticals
    12 6 0
    ABBV
    AbbVie
    13 10 0
  • Is REGN or ABBV More Risky?

    Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison AbbVie has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.364%.

  • Which is a Better Dividend Stock REGN or ABBV?

    Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie offers a yield of 3.53% to investors and pays a quarterly dividend of $1.55 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. AbbVie pays out 216.72% of its earnings as a dividend.

  • Which has Better Financial Ratios REGN or ABBV?

    Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are smaller than AbbVie quarterly revenues of $14.5B. Regeneron Pharmaceuticals's net income of $1.3B is lower than AbbVie's net income of $1.6B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while AbbVie's PE ratio is 60.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 5.61x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    REGN
    Regeneron Pharmaceuticals
    5.83x 17.37x $3.7B $1.3B
    ABBV
    AbbVie
    5.61x 60.97x $14.5B $1.6B
  • Which has Higher Returns REGN or AMGN?

    Amgen has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 33.28%. Regeneron Pharmaceuticals's return on equity of 17.19% beat Amgen's return on equity of 65.35%.

    Company Gross Margin Earnings Per Share Invested Capital
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
    AMGN
    Amgen
    61.07% $5.22 $67.9B
  • What do Analysts Say About REGN or AMGN?

    Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 22.42%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    REGN
    Regeneron Pharmaceuticals
    12 6 0
    AMGN
    Amgen
    10 15 2
  • Is REGN or AMGN More Risky?

    Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.

  • Which is a Better Dividend Stock REGN or AMGN?

    Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.42% to investors and pays a quarterly dividend of $2.25 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios REGN or AMGN?

    Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are smaller than Amgen quarterly revenues of $8.5B. Regeneron Pharmaceuticals's net income of $1.3B is lower than Amgen's net income of $2.8B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while Amgen's PE ratio is 33.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 4.37x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    REGN
    Regeneron Pharmaceuticals
    5.83x 17.37x $3.7B $1.3B
    AMGN
    Amgen
    4.37x 33.72x $8.5B $2.8B
  • Which has Higher Returns REGN or BIIB?

    Biogen has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 15.76%. Regeneron Pharmaceuticals's return on equity of 17.19% beat Biogen's return on equity of 10.52%.

    Company Gross Margin Earnings Per Share Invested Capital
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
    BIIB
    Biogen
    74.1% $2.66 $22.7B
  • What do Analysts Say About REGN or BIIB?

    Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand Biogen has an analysts' consensus of $242.83 which suggests that it could grow by 65.79%. Given that Biogen has higher upside potential than Regeneron Pharmaceuticals, analysts believe Biogen is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    REGN
    Regeneron Pharmaceuticals
    12 6 0
    BIIB
    Biogen
    13 15 0
  • Is REGN or BIIB More Risky?

    Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison Biogen has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.074%.

  • Which is a Better Dividend Stock REGN or BIIB?

    Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios REGN or BIIB?

    Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are larger than Biogen quarterly revenues of $2.5B. Regeneron Pharmaceuticals's net income of $1.3B is higher than Biogen's net income of $388.5M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while Biogen's PE ratio is 13.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 2.23x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    REGN
    Regeneron Pharmaceuticals
    5.83x 17.37x $3.7B $1.3B
    BIIB
    Biogen
    2.23x 13.23x $2.5B $388.5M
  • Which has Higher Returns REGN or LLY?

    Eli Lilly and has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 8.48%. Regeneron Pharmaceuticals's return on equity of 17.19% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
    LLY
    Eli Lilly and
    81.02% $1.07 $45.4B
  • What do Analysts Say About REGN or LLY?

    Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    REGN
    Regeneron Pharmaceuticals
    12 6 0
    LLY
    Eli Lilly and
    15 6 0
  • Is REGN or LLY More Risky?

    Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

  • Which is a Better Dividend Stock REGN or LLY?

    Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios REGN or LLY?

    Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Regeneron Pharmaceuticals's net income of $1.3B is higher than Eli Lilly and's net income of $970.3M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    REGN
    Regeneron Pharmaceuticals
    5.83x 17.37x $3.7B $1.3B
    LLY
    Eli Lilly and
    16.99x 83.00x $11.4B $970.3M
  • Which has Higher Returns REGN or PFE?

    Pfizer has a net margin of 36.03% compared to Regeneron Pharmaceuticals's net margin of 25.23%. Regeneron Pharmaceuticals's return on equity of 17.19% beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
    PFE
    Pfizer
    70.27% $0.78 $159.2B
  • What do Analysts Say About REGN or PFE?

    Regeneron Pharmaceuticals has a consensus price target of $1,053.08, signalling upside risk potential of 50.04%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    REGN
    Regeneron Pharmaceuticals
    12 6 0
    PFE
    Pfizer
    8 13 1
  • Is REGN or PFE More Risky?

    Regeneron Pharmaceuticals has a beta of 0.084, which suggesting that the stock is 91.622% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

  • Which is a Better Dividend Stock REGN or PFE?

    Regeneron Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

  • Which has Better Financial Ratios REGN or PFE?

    Regeneron Pharmaceuticals quarterly revenues are $3.7B, which are smaller than Pfizer quarterly revenues of $17.7B. Regeneron Pharmaceuticals's net income of $1.3B is lower than Pfizer's net income of $4.5B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.37x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.83x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    REGN
    Regeneron Pharmaceuticals
    5.83x 17.37x $3.7B $1.3B
    PFE
    Pfizer
    2.52x 35.62x $17.7B $4.5B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 0.73% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.55% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock